Soft tissue sarcoma, version 2.2012 Journal Article


Authors: von Mehren, M.; Benjamin, R. S.; Bui, M. M.; Casper, E. S.; Conrad, E. U. 3rd; DeLaney, T. F.; Ganjoo, K. N.; George, S.; Gonzalez, R.; Heslin, M. J.; Kane, J. M. 3rd; Mayerson, J.; McGarry, S. V.; Meyer, C.; O'Donnell, R. J.; Paz, I. B.; Pfeifer, J. D.; Pollock, R. E.; Randall, R. L.; Riedel, R. F.; Schuetze, S.; Schupak, K. D.; Schwartz, H. S.; Shankar, S.; Van Tine, B. A.; Wayne, J.; Sundar, H.; McMillian, N. R.
Article Title: Soft tissue sarcoma, version 2.2012
Abstract: The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors. © JNCCN - Journal of the National Comprehensive Cancer Network.
Keywords: cancer chemotherapy; cancer surgery; overall survival; disease course; review; sorafenib; doxorubicin; interferon; placebo; cancer radiotherapy; comparative study; postoperative care; preoperative care; methotrexate; follow up; prospective study; gastrointestinal stromal tumor; imatinib; low drug dose; progression free survival; morbidity; cancer pain; practice guideline; antineoplastic activity; retrospective study; vinblastine; high risk patient; drug dose escalation; sarcoma; celecoxib; tumor recurrence; sulindac; practice guidelines as topic; soft tissue sarcoma; tamoxifen; toremifene; desmoid tumor; recurrence free survival; randomized controlled trial (topic)
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 10
Issue: 8
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2012-08-01
Start Page: 951
End Page: 960
Language: English
PROVIDER: scopus
PUBMED: 22878820
DOI: 10.6004/jnccn.2012.0099
DOI/URL:
Notes: - "Export Date: 1 October 2012" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Karen D Schupak
    72 Schupak
  2. Ephraim S Casper
    108 Casper